Company profile
Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bupropion hydrochloride | approved | — | 1 | approved |
| Dextromethorphan hydrobromide | approved | — | 0 | — |
| Meloxicam | approved | — | 3 | approved |
| Rizatriptan Benzoate | approved | — | 11 | approved |
| Solriamfetol hydrochloride | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02746068 | phase3 | unknown | 2016-03-01 | 2020-12-01 | Axsome Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions |
| NCT05557409 | phase3 | completed | 2022-09-06 | 2024-11-21 | Axsome Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation |
| NCT02741791 | phase3 | completed | 2016-03-01 | 2020-03-20 | Axsome Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder |
| NCT05059223 | phase3 | completed | 2021-09-15 | 2024-03-15 | Axsome Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy |
| NCT07717892 | phase3 | recruiting | 2026-06-25 | 2028-06-30 | Axsome Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD |
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 211230 | NDA | AXSOME MALTA LTD | ||||
Loading… | ||||||
| NDA 215430 | NDA | AXSOME THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 215431 | NDA | AXSOME THERAPEUTICS INC | ||||
Loading… | ||||||